Avenzo Therapeutics
Avenzo Therapeutics, Inc.
Avenzo Therapeutics is a clinical-stage biotechnology company founded in 2022 and headquartered in San Diego, CA. It focuses on accelerating the development of next-generation oncology therapies by in-licensing promising drug candidates. The company has rapidly built a pipeline of four distinct assets and secured significant funding to advance them through clinical trials.
Products & Team
AVZO-021
AVZO-021 is a selective cyclin-dependent kinase 2 (CDK2) inhibitor being developed for the treatment of hormone receptor-positive (HR+) breast cancer and other solid tumors with elevated cyclin E expression. As the company's lead asset, it has progressed into a Phase 1 clinical study and is also being evaluated in combination with Gilead's Trodelvy®.
AVZO-021 addresses the need for more effective and safer treatments for specific cancer patient populations, such as those with HR+ breast cancer, by precisely targeting the CDK2 enzyme, which plays a critical role in tumor cell proliferation.
The therapies address the limitations of the current standard of care in oncology, such as drug resistance, insufficient efficacy, and significant side effects. By developing targeted and potentially more tolerable drugs, Avenzo aims to provide better treatment options for difficult-to-treat cancers.